Clinical trial · Interventional
[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer
Phase I Trial Of [18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer
NCT02297386CI-TRIAL-00034150completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to test the ability of a new PET scan radiotracer, called FDHT (stands for \[18F\] Dihydro-Testosterone), to better find and monitor prostate cancer. Radiotracers are a type of drug that carries small amounts of radioactivity that can be seen by the PET scanner. FDHT is a radiotracer that looks for a protein which is present in almost all prostate cancer cells. The investigators want to find out if we can find and monitor changes in cancer using a FDHT PET scan.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Localized Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F] DIHYDRO-TESTOSTERONE | Drug | — | UNRESOLVED |
| Blood draw | Other | — | UNRESOLVED |
| MRI | Device | — | UNRESOLVED |
| PET scan | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- [18F] DIHYDRO-TESTOSTERONE PET
- description
- The diagnostic intervention of this study is the use of FDHT PET in localized prostate cancer. Patients will undergo a 30 minute dynamic scan of the pelvis followed by a whole body scan of approximately 30-minutes duration. The dynamic scan will be optional, but strongly encouraged. PET scanning will preferably be done on the GE Discovery STE PET/CT scanner or the equivalent generation of scanner. The PET scans are routinely "quantitative," that is corrected for attenuation and scatter and adjusted for system sensitivity and providing parametric images in terms of standardized uptake values (SUV) (= μCi found/gm tissue / μCi injected/gm body mass).
- interventionNames
- Drug: [18F] DIHYDRO-TESTOSTERONE
- Device: PET scan
- Device: MRI
- Other: Blood draw
Primary outcomes (1)
- measure
- increase in standardize uptake values (SUV) between the second and third FDHT scans
- timeFrame
- 1 year
- description
- Enrolling 15 patients will provide 80% power to detect a 33% increase in the mean uptake (from 6 to 8) between the 2nd and the 3rd scans.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 21 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: * Male aged 21 years or older and below 80 years of age. * Signed written informed consent and willingness to comply with protocol requirements. * Histologically confirmed diagnosis of prostate cancer. * Staging imaging workup including a baseline MRI of the prostate and pelvis performed at MSKCC. * Baseline imaging to rule out distant metastatic disease (99mTc bone scan, NaF PET, total body MRI, or CT chest/abdomen/pelvis) * Karnofsky performance status ≥ 70 * Clinical criteria required to be eligible: a. One of the following i.Pre-treatment PSA ≥10 ng/dL, OR ii. Clinical T-stage assessed by digital rectal exam of ≥T2a, OR ii . Radiographic ≥T3a on MRI, OR iv. Gleason score of ≥3+4=7 c. Visible intraprostatic tumor foci ≥1 cm in largest dimension on T2-weighted images based on initial pre-treatment MRI * Physician recommendation of ADT. Exclusion Criteria: * Metastatic disease on standard staging imaging (beyond regional lymph node involvement). o Absence of metastatic disease (beyond regional lymph node involvement) as defined by a negative bone scan, NaF PET, CT chest/abdomen/pelvis, or total body MRI. * Prior treatment of the prostate gland for malignant conditions (surgery, cryotherapy, radiotherapy, or photodynamic therapy). * Physician prescription of androgen receptor antagonist therapy (examples: bicalutamide, flutamide, or enzalutamide) during time of protocol scans. o Note: ADT consists of chemical castration (i.e. degarelix) to remove endogenous DHT. Androgen receptor antagonists will bind to the androgen receptor and inhibit FDHT from binding. * Patients receiving testosterone supplementation . * Any contraindication to baseline MRI based on departmental MR questionnaire, or inability to cooperate for an MRI scan. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to FDHT. * Hepatic laboratory values: 1. Bilirubin \>1.5 x ULN (institutional upper limits of normal) 2. AST/ALT \>2.5 x ULN 3. Albumin \<2 g/dL * Creatinine \>2.5 mg/dL * Calcium \>11 mg/dL * Other serious illness(es) which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.
References
Publications (0)
Data not yet available
No reference posted for this study.